KRONOS BIO INC. - COM

Kronos Bio Enters into Agreement to Be Acquired by Concentra Biosciences for $0.57 in Cash per Share Plus a Contingent Value Right

01 May 2025 08:30:00 By Nasdaq GlobeNewswire

Kronos Bio Reports Fourth Quarter and Full Year 2024 Financial Results

18 Mar 2025 16:01:00 By Nasdaq GlobeNewswire

Kronos Bio Announces CEO Transition and Reduction in Force

27 Nov 2024 07:30:00 By Nasdaq GlobeNewswire

Kronos Bio Highlights Preclinical Data that Show p300 KAT Inhibitors Reduce Inflammation in an Oral Presentation at ACR Convergence 2024

14 Nov 2024 16:02:00 By Nasdaq GlobeNewswire

Kronos Bio Reports Third Quarter 2024 Financial Results and Corporate Update Including Plan to Evaluate Strategic Alternatives

13 Nov 2024 16:05:00 By Nasdaq GlobeNewswire

Kronos Bio to Present Data at the ASH Annual Meeting from p300 KAT Inhibition Program in Multiple Myeloma

05 Nov 2024 09:00:01 By Nasdaq GlobeNewswire

Kronos Bio Data Presentation at EORTC-NCI-AACR Symposium Highlights the Importance of p300 KAT Inhibition in HPV-Driven Tumors

23 Oct 2024 08:55:00 By Nasdaq GlobeNewswire

Kronos Bio to Present Data at the EORTC-NCI-AACR Symposium that Supports p300 KAT Inhibition in HPV-Driven Tumors

09 Oct 2024 08:55:00 By Nasdaq GlobeNewswire

Kronos Bio Announces Selection of Autoimmune Development Candidate for Sjögren’s Disease

07 Oct 2024 08:55:00 By Nasdaq GlobeNewswire

Kronos Bio to Present Data at ACR Convergence 2024 to Support p300 KAT Inhibition as an Approach to Anti-Inflammatory Therapy

25 Sep 2024 08:55:00 By Nasdaq GlobeNewswire

Kronos Bio Highlights Data at AACR Ovarian Cancer Research Symposium that Supports Clinical Evaluation of Istisociclib in Advanced Ovarian Cancer

23 Sep 2024 08:55:00 By Nasdaq GlobeNewswire

Kronos Bio Announces Participation in Medical and Investor Conferences in September

03 Sep 2024 08:55:00 By Nasdaq GlobeNewswire

Kronos Bio Reports Second Quarter 2024 Financial Results and Pipeline Update

08 Aug 2024 16:15:00 By Nasdaq GlobeNewswire

Kronos Bio Announces First Patient Dosed with KB-0742 in an Expansion Cohort Focused on Platinum-Resistant High-Grade Serous Ovarian Cancer

23 Jul 2024 16:15:00 By Nasdaq GlobeNewswire

Kronos Bio to Present Clinical Update on Phase 1/2 Trial of KB-0742 at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

23 May 2024 17:15:00 By Nasdaq GlobeNewswire

Kronos Bio to Participate in Three Upcoming Healthcare Conferences and Events

22 May 2024 16:30:00 By Nasdaq GlobeNewswire

Kronos Bio Appoints Deborah Knobelman, Ph.D. as Chief Operating Officer and Chief Financial Officer 

21 May 2024 08:15:00 By Nasdaq GlobeNewswire

Kronos Bio Reports First-Quarter 2024 Financial Results

09 May 2024 16:05:00 By Nasdaq GlobeNewswire

Kronos Bio to Present Clinical Update on Phase 1/2 Trial of KB-0742 at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

24 Apr 2024 16:01:00 By Nasdaq GlobeNewswire

Kronos Bio Reports Recent Business Progress and Fourth-Quarter and Full-Year 2023 Financial Results

21 Mar 2024 07:05:00 By Nasdaq GlobeNewswire